Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Pacira BioSciences Inc’s stock clocked out at $15.66, down -2.06% from its previous closing price of $15.99. In other words, the price has decreased by -$2.06 from its previous closing price. On the day, 0.92 million shares were traded. PCRX stock price reached its highest trading level at $16.11 during the session, while it also had its lowest trading level at $15.64.
Ratios:
To gain a deeper understanding of PCRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.91. For the most recent quarter (mrq), Quick Ratio is recorded 5.70 and its Current Ratio is at 6.82. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on August 13, 2024, Downgraded its rating to Sell and sets its target price to $8 from $30 previously.
On August 12, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $37 to $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when GAUGLER DARYL sold 500 shares for $12.86 per share. The transaction valued at 6,430 led to the insider holds 115,700 shares of the business.
GAUGLER DARYL bought 500 shares of PCRX for $6,430 on Sep 13 ’24. On Aug 16 ’24, another insider, BIGAL MARCELO, who serves as the Director of the company, bought 1,512 shares for $13.25 each. As a result, the insider paid 20,034 and bolstered with 10,142 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 722347264 and an Enterprise Value of 981938880. As of this moment, Pacira’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.17, and their Forward P/E ratio for the next fiscal year is 5.19. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.05 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at 1.422 whereas that against EBITDA is 5.6.
Stock Price History:
Over the past 52 weeks, PCRX has reached a high of $35.95, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 2.27%, while the 200-Day Moving Average is calculated to be -38.07%.
Shares Statistics:
It appears that PCRX traded 1.28M shares on average per day over the past three months and 786130 shares per day over the past ten days. A total of 46.48M shares are outstanding, with a floating share count of 44.59M. Insiders hold about 3.33% of the company’s shares, while institutions hold 114.13% stake in the company. Shares short for PCRX as of 1726185600 were 5746834 with a Short Ratio of 4.49, compared to 1723680000 on 5154205. Therefore, it implies a Short% of Shares Outstanding of 5746834 and a Short% of Float of 18.15.
